SIGA Technologies announces FDA submission of NDA for oral TPOXX (tecovirimat)
SIGA Technologies announced submission of its NDA to the FDA for the oral formulation of TPOXX® (tecovirimat). TPOXX was developed to treat smallpox, as well as other orthopoxvirus infections. The advanced development of TPOXX has been funded by the BARDA. December 11, 2017